Chinwe A Ndueche,
Uyi M Ogbeide
,
Henry A Okeri
For correspondence:- Uyi Ogbeide Email: uyi.ogbeide@uniben.edu Tel: +2347038058676
Citation: Ndueche CA, Ogbeide UM, Okeri HA. Colorimetric Determination of Meloxicam in Bulk and Tablet Dosage Forms. J Sci Pract Pharm 2022; 9(1):465-473 doi: 10.47227/jsppharm.v9i1.3
© 2022 The author(s).
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only. .
Purpose: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) which belongs to the oxicam class used in the management of pain and inflammation. This research aims to develop a simple, sensitive, accurate, reproducible and affordable method of determination of meloxicam in bulk and tablet dosage forms. Methods: The method involves oxidation of meloxicam (in sodium hydroxide) with potassium permanganate at room temperature and determination of the wavelength of maximum absorption (λmax) of the oxidized product. The reaction conditions were optimized and the developed method was used to determine the percentage content of the drug in bulk and tablet dosage forms. The validation of the method was carried out using the guideline designated by the International Council for Harmonization of Technical Requirement for Registration of Pharmaceuticals for Human Use (ICH). Results: The results show that the wavelength of maximum absorption of the oxidized product was 610 nm and all measurements were taken at this wavelength. The equation of regression line for the Beer’s plot was: A = 0.067C + 0.017 (R2 = 0.9965) and the calibration plot was linear over a concentration range of 1.56 – 9.37 µg/mL with molar absorptivity of 2.3820 × 10 4 L/mol/cm. The limit of detection (LOD) and limit of quantification (LOQ) are 0.3238 and 1.0930, respectively, while the relative standard deviation (RSD) in the intra and inter-day analyses were between 0.16 - 0.18% and 0.21 - 0.29%, respectively. The method was applied for quantitative analysis of meloxicam in tablet dosage form and the percentage recovery was found to be within the range of 97.11 – 100.89%. Conclusion: The proposed method was considered accurate, simple and can produce reproducible results. This method can be used for the routine assay of meloxicam in bulk and tablet formulation.
